These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31534205)

  • 21. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
    Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
    J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.
    Ji C; Roy MD; Golas J; Vitsky A; Ram S; Kumpf SW; Martin M; Barletta F; Meier WA; Hooper AT; Sapra P; Khan NK; Finkelstein M; Guffroy M; Buetow BS
    Clin Cancer Res; 2019 Aug; 25(15):4735-4748. PubMed ID: 31085720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy.
    Nishimura T; Ninomiya K; Nakashima M; Akagi S; Kuribayashi T; Higo H; Hotta K; Maeda Y; Ito H; Kiura K
    Intern Med; 2023 May; 62(9):1319-1322. PubMed ID: 36130891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKI in Patients Receiving Immune Checkpoint Inhibitors.
    Perazella MA; Sprangers B
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
    [No Abstract]   [Full Text] [Related]  

  • 30. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
    Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
    Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
    Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
    Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
    Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.
    Giblin GT; Dennehy C; Featherstone H; Clarke R; Murphy L; Timlin D; O'Keane C; Mulligan N; Kelly CM; Joyce E
    Circ Heart Fail; 2021 Feb; 14(2):e007524. PubMed ID: 33478241
    [No Abstract]   [Full Text] [Related]  

  • 34. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
    Prevel R; Colin G; Calès V; Renault PA; Mazieres J
    Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
    Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
    Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
    N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
    [No Abstract]   [Full Text] [Related]  

  • 37. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice.
    Tang X; Li Y; Huang H; Shi R; Shen LT; Qian WL; Yang ZG
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8345-8357. PubMed ID: 37076643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
    Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
    Front Oncol; 2021; 11():658690. PubMed ID: 34150625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
    Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
    Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
    [No Abstract]   [Full Text] [Related]  

  • 40. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.